Inhibition of fatty acid synthase suppresses c-Met receptor kinase and induces apoptosis in diffuse large B-Cell lymphoma

Molecular Cancer Therapeutics

Volumn 9, Issue 5, 2010, Pages 1244-1255

  Uddin, Shahab ^a   Hussain, Azhar R ^a   Ahmed, Maqbool ^a   Bu, Rong ^a   Ahmed, Saeeda O ^a   Ajarim, Dahish ^b   Al Dayel, Fouad ^b   Bavi, Prashant ^a   Al Kuraya, Khawla S ^b  

^a Research Center   (United States)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; C 75; CASPASE; FATTY ACID SYNTHASE; KI 67 ANTIGEN; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DRUG TARGETING; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LARGE CELL LYMPHOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY;

4-BUTYROLACTONE; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; VALIDATION STUDIES AS TOPIC;

EID: 77952210907     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-1061     Document Type: Article

References (46)

1. Savage KJ, Shipp MA. Initial evaluation: staging and prognostic factors. In: Mauch LP, Armitage J, Harris N, Dalla-Favera R, Coiffer B, editors. Non-Hodgkin's lymphoma. Philadelphia (PA): Lippincott Williams and Wilkins; 2004, p. 97-125.
2. Asturias FJ, Chadick JZ, Cheung IK, et al. Structure and molecular organization of mammalian fatty acid synthase. Nat Struct Mol Biol 2005;12:225-232
3. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry 1989;28:4523-4530
4. Milgraum LZ, Witters LA, Pasternack GR, Kuhajda FP. Enzymes of the fatty acid synthesis pathway are highly expressed in in-situ breast carcinoma. Clin Cancer Res 1997;3:2115-2120
5. Uddin S, Siraj AK, Al-Rasheed M, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008;93:4088-4097
6. Kuhajda FP. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000;16:202-208
7. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006;66:5977-5980
8. Wang HQ, Altomare DA, Skele KL, et al. Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells. Oncogene 2005;24:3574-3582
9. Pizer ES, Pflug BR, Bova GS, Han WF, Udan MS, Nelson JB. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001;47:102-110
10. Baron A, Migita T, Tang D, Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer? J Cell Biochem 2004;91:47-53.
11. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-777 (Pubitemid 47469806)
12. Pizer ES, Wood FD, Pasternack GR, Kuhajda FP. Fatty acid synthase (FAS): a target for cytotoxic antimetabolites in HL60 promyelocytic leukemia cells. Cancer Res 1996;56:745-751
13. Wang WQ, Zhao XY, Wang HY, Liang Y. Increased fatty acid synthase as a potential therapeutic target in multiple myeloma. J Zhejiang Univ Sci B 2008;9:441-447
14. Menendez JA, Vellon L, Mehmi I, et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004;101:10715-10720
15. Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther 2009;8:214-224
16. van der Voort R, Taher TE, Derksen PW, et al. The hepatocyte growth factor/Met pathway in development, tumorigenesis, and B-cell differentiation. Adv Cancer Res 2000;79:39-90.
17. Hsiao LT, Lin JT, Yu IT, et al. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma. Eur J Haematol 2003;70:282-289
18. Kawano R, Ohshima K, Karube K, et al. Prognostic significance of hepatocyte growth factor and c-Met expression in patients with diffuse large B-cell lymphoma. Br J Haematol 2004;127: 305-307
19. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008;93:611-618 (Pubitemid 351240838)
20. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. Lyon: IARC; 2001.
21. Bavi P, Jehan Z, Atizado V, et al. Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1708-1718 (Pubitemid 44497108)
22. McCarty KS, Jr., Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109: 716-721
23. Uddin S, Hussain AR, Siraj AK, et al. Role of phosphatidylinositol 3′-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108:4178-4186
24. Abubaker J, Bavi P, Al-Harbi S, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-3545 (Pubitemid 351793794)
25. Uddin S, Hussain AR, Ahmed M, et al. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B cell lymphoma. J Pathol 2008;216:483-494
26. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275-282
27. Bavi P, Abubaker J, Hussain A, et al. Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885-894
28. Hussain AR, Al-Rasheed M, Manogaran PS, et al. Curcumin induced apoptosis in Acute T cell Leukemia. Apoptosis 2006;11: 245-254
29. Hussain AR, Al-Jomah NA, Siraj AK, et al. Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res 2007;67:3888-3897
30. Uddin S, Hussain AR, Manogaran PS, et al. Curcumin suppresses growth and induces apoptosis in primary effusion lymphoma. Oncogene 2005;24:7022-7030
31. Hussain AR, Ahmed M, Al-Jomah NA, et al. Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell lines. Mol Cancer Ther 2008;7:3318-3329
32. Uddin S, Ah-Kang J, Ulaszek J, et al. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc Natl Acad Sci U S A 2004;101: 147-152
33. Uddin S, Hussain AR, Al-Hussein KA, et al. Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 2005;11:3102-3108
34. del Peso L, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997;278:687-689
35. Shin I, Bakin AV, Rodeck U, Brunet A, Arteaga CL. Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 2001;12: 3328-3339
36. Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001;292:727-730
37. Ho TS, Ho YP, Wong WY, et al. Fatty acid synthase inhibitors Cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells. Biomed Pharmacother 2007;61:578-587
38. Migita T, Ruiz S, Fornari A, et al. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst 2009;101:519-532
39. Tjin EP, Groen RW, Vogelzang I, et al. Functional analysis of HGF/c-Met signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood 2006;107:760-768
40. Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem 2005;280: 5636-5645
41. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-1 preadipocyte differentiation induction. J Biol Chem 2003;278: 11561-11569
42. Wang L, Zhao YF, Li YL, Xu YF, Xia Q, Ma KL. Effects of lipid rafts on signal transmembrane transduction mediated by c-Met. Zhonghua Gan Zang Bing Za Zhi 2008;16:449-452
43. Swinnen JV, Van Veldhoven PP, Timmermans L, et al. Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains. Biochem Biophys Res Commun 2003;302:898-903.
44. Pizer ES, Jackisch C, Wood FD, et al. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res 1996;56:2745-2747
45. Björck E, Ek S, Landgren O, et al. High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood 2005;105:2908-2915
46. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 1997;89:601-609